4/A: Neurogene Director Corrects SEC Filing CIK Error
Form 4/A (Amendment)
Director Keith Woods filed an amendment to a Form 4 to correct a CIK number error regarding a previously reported stock option grant.
Summary
- Director Keith Woods received a grant of 12,050 non-qualified stock options on June 12, 2025.
- The options have an exercise price of $20.40 and are fully vested.
- The filing is an amendment to a June 13, 2025, filing to correct an incorrect CIK number used for the reporting person.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative correction with no impact on the company's fundamental outlook.
Positives
- The amendment demonstrates proactive compliance and attention to regulatory detail by correcting administrative errors.
Negatives
- The initial filing contained an administrative error regarding the reporting person's CIK number.
Risks
- None identified; this is a routine administrative correction.
Future Outlook
No forward-looking guidance provided in this administrative filing.
Industry Context
StockSavvy.ai notes that administrative amendments to SEC filings are common and generally do not reflect changes in company strategy or financial health.
Comparison to Industry Standards
- The grant of fully vested stock options to directors is a standard practice in the biotechnology sector to align interests with shareholders.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Keith Woods authorized several company representatives to file SEC reports on his behalf. | 06/12/2025 | Standard administrative procedure to ensure timely regulatory compliance. |
Stakeholder Impact
- No material impact on shareholders, employees, or creditors.
Next Steps
- None identified.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date of the stock option grant and execution of Power of Attorney. |
| 06/13/2025 | Date of the original, incorrect filing. |
| 06/16/2026 | Date of the amended filing signature. |
Keywords
Neurogene, NGNE, Form 4, Director, Stock Options, SEC Filing, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.